Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

This activity is supported by an educational grant from AstraZeneca.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers

Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers

March 10th, 2017
10:30 AM – 12:00 PM

Miami Beach
4441 Collins Avenue
Miami Beach, FL 33140
Reservation: 800-548-8886


“Medical Crossfire®: Clinical Updates on PARP inhibition and its Evolving Use in the Treatment of Cancers” is a live continuing medical and nursing education (CME/CE)-certified symposium to be held adjunct to the 34th Annual Miami Breast Cancer Conference®, a PER® Legacy International Conference.

Poly (ADP-ribose) polymerase (PARP) inhibitors have garnered a great deal of clinical interest as a means of treating a variety of human cancers, with several therapeutic options currently in late-stage clinical development. With recent advancements in the understanding of tumor-defining molecular changes, use of PARP inhibitors has been shown to be efficacious as a cytotoxic strategy in the treatment of patients with breast and other gynecologic cancers. Clinical trial evidence continues to accumulate at a rapid pace. The placement of this evidence in the context of changing treatment paradigms for patients with breast cancer requires informed discussion.

To that end, we are bringing together a panel of internationally recognized experts in breast cancer therapy to facilitate the exchange of ideas and explore best practices regarding the potential impact of PARP inhibitors on the treatment landscape. Faculty will cover several key topics, including:

  • DNA damage response as a targeted therapy
  • Testing for germline/somatic mutations when considering PARP inhibition
  • Assessment of clinical trial evidence pertaining to PARP inhibition for different tumors
  • Influence of PARP inhibition strategies on breast cancer management

The symposium will be held at the Fontainebleau Miami Beach on March 10 from 10:30AM–12:00PM. Please join us live in Miami to learn the latest and greatest state-of-the-art science around PARP inhibitor therapies, as well as the most up-to-date information on appropriate and optimal use of these agents.

This CME/CE-certified symposium will provide a valuable opportunity to enhance your knowledge of PARP inhibitor therapy and learn from leading clinicians. We look forward to seeing you!

Target Audience

This educational activity is intended for all attendees of the Miami Breast Cancer Conference®, which includes medical, radiation, and surgical oncologists whose primary practice focus is breast cancer. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the treatment and management of breast cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain tumor biology mechanisms that provide the rationale for targeting PARP in the treatment of cancers
  • Assess emerging data concerning the application of PARP inhibitors in the treatment of breast cancer and how this applies to personalization of management/counseling for patients with these tumors and their families
  • Apply lessons learned from PARP inhibitor strategies for ovarian cancer in the context of an evolving treatment landscape for patients with breast cancer

Program Chair

Mark Robson, MD
Clinical Director
Genetics Service
Memorial Sloan Kettering Cancer Center


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information



Become a Member

Forgot Password?
Calendar of Events
Filter By